Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

hwmccusker 6 posts  |  Last Activity: Jul 31, 2015 10:29 AM Member since: Jan 8, 2010
  • What some will do for the next fee, having collected it once at his previous firm - Wainright to Raymond/James!
    Also it indicated that CAPR will be in the market again – dilution and share price be damned! Every day, it becomes a target for trading short volume and price swings. I haven’t been WRONG.

    Sentiment: Strong Sell

  • Buy ANY shares in the last offering - that is the metric of ownership and belief of their capacity and capability to produce results other than inhabiting the CEOs former building - remember that company - FAILED!

    Sentiment: Strong Sell

  • The pricing pressure will continue as who in their right mind, in review of the continuous sells and pricing actions would respond to a purchase with the probability of downward momentum being so acute! The $7 M and $10 M H.C. Wainwright private placements were put into fast money hands - thus a "tough" result; the HCW analyst left for another firm and I would say CAPR is negotiating with another firm for a raise!!

    Sentiment: Strong Sell

  • Boy or women, do we miss … 3/18/15’s $10.35! All you have to do is marry the research director with NO experience as a CEO combined with a director of finance with minimal public company experience and exposure and voila - as long as you “con” certain members of the BOD – who should fulfill their roles - it works. A lot of issues re the role of leadership and interaction – so where is the PR counsel (?) to right the wrongs or clear and support the “rights” of shareholders – Have been RIGHT for weeks - STRONG SELL;

    Sentiment: Strong Sell

  • Mr. McGorry has more than 25 years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. He also has been a member of the HART Board of Directors since 2/13.
    Mr. McGorry most recently served as EVP and General Manager, Translational Oncology Solutions for Champions Oncology and previously was EVP of Commercial Operations at Accellent.
    During his 12-year tenure at Genzyme, he held leadership positions across several therapeutic areas, including Bio Surgery, Cardiac Surgery, Oncology and Transplant. Mr. McGorry also was President of Clineffect Systems, an electronic medical records company. He began his life sciences career with Baxter, where he spent 11 years in positions of increasing responsibility.
    Mr. McGorry has an MBA with a concentration in healthcare from Duke University, Fuqua School of Business and a B.S. in engineering from the United States Military Academy at West Point where he was the president of his class. Mr. McGorry also served as an officer in the US Army for six years, including commanding a special operations Green Beret SCUBA detachment.

    Sentiment: Buy

  • There all about protecting what they have without projecting what the should be doing about cost inefficiencies, overhead, burn, corporate comp and facilitating their "own" agendas - look at the ... too far away Basking Ridge office at 106 Allen Street from HQ in NYC where almost all employees are located. . Does the bank account reflect an input of $17.7 m from CIRM - NO, it is overtime based on milestone and 40/60 matching for each dollar spent. Management should be more specific re the truths of the status. The most recent offering was just a ... vehicle for the shorts to "cover". And, then look at the blossoming usage of the ATM - still debt with a sliding time factor ... into the daily/weekly/monthly market ...affecting the share pricing

    Sentiment: Strong Sell

SVFC
0.00010.0000(0.00%)Sep 2 2:14 PMEDT